Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Active, not recruiting · NCT03918252 · Registry updated 2026-06-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | Neoplasms by Histologic Type, adenoma, epithelial neoplasm, mesothelial neoplasm, mesothelioma, neoplasm | Active, not recruiting | Phase 2 | 2026-06-05 | NCT03918252 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine | Baltimore | United States | 1 |
| Johns Hopkins University | Baltimore | United States | 150 |
| University of Texas M.D. Anderson Cancer Center | Houston | United States | 9 |